Upon hearing about the war on drugs, many of us in medicine immediately become skeptical. Same old, same old—nothing seems to change. Yet this year, new healthcare codes for drug screening and intervention have been developed. Can these new efforts make a difference? Our guest today is Dr. Bertha Madras who serves as the Deputy Director of Demand Reduction in the White House office of National Drug Control Policy. Prior to this government post, she was Professor of Psychobiology in the Department of Psychiatry at Harvard Medical School. She is an expert on drug addiction and has authored over 130 papers and book chapters as well as receiving 16 patents.
War on Drugs: New CPT codes for screening and RX
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Overview
Upon hearing about the war on drugs, many of us in medicine immediately become skeptical. Same old, same old—nothing seems to change. Yet this year, new healthcare codes for drug screening and intervention have been developed. Can these new efforts make a difference? Our guest today is Dr. Bertha Madras who serves as the Deputy Director of Demand Reduction in the White House office of National Drug Control Policy. Prior to this government post, she was Professor of Psychobiology in the Department of Psychiatry at Harvard Medical School. She is an expert on drug addiction and has authored over 130 papers and book chapters as well as receiving 16 patents.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Partnering with Patients: Building Effective Communication and Support in HF Care
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?